| Literature DB >> 34882721 |
Han Jo Jeon1, Hyuk Soon Choi1, Eun Ju Bang1, Kang Won Lee1, Sang Hyun Kim1, Jae Min Lee1, Eun Sun Kim1, Bora Keum1, Yoon Tae Jeen1, Hong Sik Lee1, Hoon Jai Chun1, Seung Jeong2, Jong Hyuk Kim3,4.
Abstract
Injectable thermo-sensitive chitosan hydrogels have recently been developed for the use of submucosal fluids in endoscopic submucosal dissections (ESD). This study aimed to investigate the efficacy and safety of chitosan hydrogels during ESD. Submucosal fluids were administered as follows: 0.9% normal saline (NS), 0.4% hyaluronic acid (HA) and chitosan/β-glycerophosphate (CS/GP) hydrogel. Each solution was administered twice into the stomach and colon of a pig, with a total of 72 ESD procedures performed on 12 pigs. The injected volume and procedure-related parameters were recorded and analyzed. ESDs that created ulcers after 7 days were histologically compared. All ESD specimens were resected en bloc. The total injected volumes during ESD of the stomach (NS, 16.09±3.27 vs. HA, 11.17±2.32 vs. CS/GP, 9.44±2.33; p<0.001) and colon (NS, 9.17±1.80 vs. HA, 6.67±1.50 vs. CS/GP, 6.75±1.57; p = 0.001) were significantly different. Hydrogel showed significant differences from normal saline in terms of fluid power (mm2/vol; NS, 35.70±9.00 vs. CS/GP 57.48±20.77; p = 0.001) and consumption rate (vol/min; NS, 2.59±0.86 vs. CS/GP, 1.62±0.65; p = 0.013) in the stomach. Histological examination revealed preserved muscularis propria, although the chitosan hydrogel resulted in a partial inflammatory response, with a hypertrophied submucosal layer. Chitosan hydrogel was found to be superior to normal saline, with an efficacy similar to that of hyaluronic acid. Nonetheless, long-term histological changes should be evaluated before clinical implementation.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34882721 PMCID: PMC8659419 DOI: 10.1371/journal.pone.0260458
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Schematic flow chart of experiments.
Random allocation of submucosal fluids according to location.
|
| Pig 1 | Pig 2 | Pig 3 | Pig 4 | Pig 5 | Pig 6 | Pig 7 | Pig 8 | Pig 9 | Pig 10 | Pig 11 | Pig 12 |
| Antrum 1 | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA |
| Antrum 2 | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP |
| Body | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS |
|
| Pig 1 | Pig 2 | Pig 3 | Pig 4 | Pig 5 | Pig 6 | Pig 7 | Pig 8 | Pig 9 | Pig 10 | Pig 11 | Pig 12 |
| AV 20cm | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA |
| AV 40cm | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP |
| AV 60cm | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS | CS/GP | HA | NS |
NS, 0.9% normal saline; HA, 0.4% hyaluronic acid; CS/GP, chitosan/β-glycerophosphate; AV; anal verge; Antrum 1, Antrum/Greater curvature; Antrum 2, Antrum/Anterior wall.
Fig 2Endoscopic view of submucosal dissection procedure according to solution.
(A) 0.9% normal saline (B) 0.4% hyaluronic acid (C) chitosan/β-glycerophosphate (first row, marking; second row, injection; third row, precutting; fourth row, dissection).
Comparative gastric endoscopic submucosal dissection-related parameters between solutions.
| Stomach | NS (n = 12) | HA (n = 12) | CS/GP (n = 12) | p-value |
| Total volume (mL) | 16.09±3.27 | 11.17±2.32 | 9.44±2.33 | <0.001 |
| Initial volume | 10.99±2.22 | 8.63±2.20 | 7.95±1.26 | 0.001 |
| Additional volume | 5.10±2.28 | 2.54±0.62 | 1.49±1.32 | <0.001 |
| Injection number | 0.332 | |||
| 1 | 0/12 (0.0%) | 2/12 (16.7%) | 3/12 (25.0%) | |
| 2 | 11/12 (91.7%) | 10/12 (83.3%) | 9/12 (75.0%) | |
| 3 | 1/12 (8.3%) | 0/12 (0.0%) | 0/12 (0.0%) | |
| Procedure time (min) | 14.92±4.44 | 15±2.98 | 14.08±2.87 | 0.780 |
| Dissection time (min) | 6.92±2.81 | 6.58±2.19 | 6.42±2.27 | 0.878 |
| Dissection speed (cm2/min) | 88.99±28.53 | 93.62±39.36 | 92.40±41.79 | 0.951 |
| Power (cm2/mL) | 35.70±9.00 | 47.74±7.90 | 57.48±20.77 | 0.002 |
| Consumption rate (mL/min) | 2.59±0.86 | 1.80±0.82 | 1.62±0.65 | 0.011 |
| ESD area (mm2) | 566.07±161.46 | 532.49±128.68 | 533.65±202.80 | 0.856 |
| ESD complication | ||||
| Bleeding | 2/12 (0%) | 1/12 (0%) | 2/12 (0%) | 1.000 |
| Perforation | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | 1.000 |
| En-bloc resection | 100% | 100% | 100% | 1.000 |
ESD, endoscopic submucosal dissection; NS, 0.9% normal saline; HA, 0.4% hyaluronic acid; CS/GP, chitosan/β-glycerophosphate.
a, ANOVA (analysis of variance).
b, Fisher’s exact test.
All values are significant at p < 0.05 level.
Normality test was significant at p > 0.05 level.
Post hoc analysis of endoscopic submucosal dissection parameters.
| NS | NS | HA | |
|---|---|---|---|
| vs | vs | vs | |
| HA | CS/GP | CS/GP | |
|
| |||
| Total volume | <0.001 | <0.001 | 0.269 |
| Initial volume | 0.014 | 0.002 | 0.674 |
| Additional volume | <0.001 | <0.001 | 0.241 |
| Fluid Power | 0.099 | 0.001 | 0.211 |
| Consumption rate | 0.049 | 0.013 | 0.838 |
|
| |||
| Total volume | 0.002 | 0.003 | 0.991 |
| Initial volume | 0.116 | 0.286 | 0.865 |
| Additional volume | 0.035 | 0.01 | 0.836 |
| Fluid Power | 0.449 | 0.506 | 0.995 |
| Consumption rate | 0.299 | 0.291 | 1.000 |
NS, 0.9% normal saline; HA, 0.4% hyaluronic acid; CS/GP, chitosan/β-glycerophosphate.
a, Tukey post-hoc.
b, Mann-Whitney post-hoc.
*, p-value < 0.167 in accordance with Bonferroni correction.
Comparative colonic endoscopic submucosal dissection-related parameters between solutions.
| Colon | NS (n = 12) | HA (n = 12) | CS/GP (n = 12) | p-value |
|---|---|---|---|---|
| Total volume (mL) | 9.17±1.80 | 6.67±1.50 | 6.75±1.57 | 0.001 |
| Initial volume | 7.17±1.85 | 5.83±1.34 | 6.17±1.54 | 0.118 |
| Additional volume | 2.00±1.19 | 0.83±1.40 | 0.58±0.97 | 0.002 |
| Injection number | 0.060 | |||
| 1 | 3/12 (25.0%) | 8/12 (66.7%) | 8/12 (66.7%) | |
| 2 | 9/12 (75.0%) | 3/12 (25.0%) | 4/12 (33.3%) | |
| 3 | 0/12 (0.0%) | 1/12 (8.3%) | 0/12 (0.0%) | |
| Procedure time (min) | 11.33±1.92 | 10.17±2.37 | 9.67±2.53 | 0.203 |
| Dissection time (min) | 6.83±1.70 | 6.17±2.12 | 6.08±1.78 | 0.568 |
| Dissection speed (cm2/min) | 59.67±26.02 | 59.02±27.55 | 55.02±17.59 | 0.878 |
| Power (cm2/mL) | 41.89±16.15 | 53.07±23.32 | 52.17±26.46 | 0.407 |
| Consumption rate (mL/min) | 1.41±0.43 | 1.18±0.40 | 1.18±0.30 | 0.230 |
| ESD area (mm2) | 373.36±131.30 | 338.98±139.84 | 341.86±164.64 | 0.816 |
| ESD complication | ||||
| Bleeding | 1/12 (8.3%) | 0/12 (0.0%) | 2/12 (16.7%) | 1.000 |
| Perforation | 0/12 (0.0%) | 0/12 (0.0%) | 0/12 (0.0%) | 1.000 |
| En-bloc resection | 100% | 100% | 100% | 1.000 |
ESD, endoscopic submucosal dissection; NS, 0.9% normal saline; HA, 0.4% hyaluronic acid; CS/GP, chitosan/β-glycerophosphate.
All values are significant at p < 0.05 level.
Normality test was significant at p > 0.05 level.
a, ANOVA (analysis of variance).
b, Kruskal-Wallis test.
c, Fisher’s exact test.
Fig 3Histologic representation of endoscopic submucosal dissection (ESD) induced ulcer after 7 days.
The first and second row indicate gastric and colonic ulcers after ESD, respectively. Administered by (A) normal saline and (B) 0.4% hyaluronic acid revealing a microscopically sharply demarcated ulcer (arrow) without hemorrhage (asterisk), and by (C) chitosan/β-glycerophosphate, presenting a loss of the mucosal layer with a hypertrophied submucosal layer (asterisk) at the ulcer base. Hematoxylin-Eosin (H & E) stain; x40. The colonic ulcer injected by (D) normal saline, (E) 0.4% hyaluronic acid showing a smooth margin without hemorrhage and perforation (asterisk), and (F) a chitosan/β-glycerophosphate ulcer presenting with a thickened submucosal layer (asterisk), and focal lysis (arrow) with granulation tissue, H & E; x40, (G) The gastric tissue administered with chitosan/β-glycerophosphate solution exhibiting focal cell lysis (asterisk) and fibrinolysis (arrow), which is indicative of minimal hemorrhaging (strong pink). H & E; x200.